IDEAYA Biosciences Inc. (IDYA) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, IDEAYA Biosciences Inc. (NASDAQ: IDYA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $31.64 (-1.00% 1D, market cap $3.08B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IDYA ranks #620 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IDYA carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -13.8%. By comparison, TLX (Telix Pharmaceuticals Limited) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.08B) and BHC (Bausch Health Companies Inc.) posts a C+ grade (68/100 RQD, P/E 21.2x, ROIC 7.6%, cap $3.07B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
Per IDYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001676725), IDEAYA Biosciences Inc. generated $218.7M in revenue (+3024.4% YoY), -$113.7M in net income, and -$73.5M in free cash flow against $1.11B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 21.49 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While IDYA currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($36.95) and Max Pain ($33.22) forces dealer call-delta covering toward $44.81.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
IDEAYA Biosciences Inc. (IDYA) slipped -1.00% to $31.64, trading at 30% of its 52-week range ($26.81 – $42.68). Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
PR Newswire report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
IDEAYA Biosciences (IDYA) moved into focus after updated ESMO 2026 data for IDE849 in relapsed small cell lung cancer and neuroendocrine carcinomas, and for darovasertib in metastatic and primary uveal melanoma. Despite
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +3024.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IDYA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IDYA. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, IDEAYA Biosciences Inc. (IDYA) ranks #620 by composite RQD confidence (34/100, grade E) and #201 by equity capitalization ($3.08B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with IDYA at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IDYA
ACTIVE
IDEAYA Biosciences Inc. | E | 34/100 | — | — | -13.8% | -1.00% | $3.08B | Benchmark Subject |
| TLX Telix Pharmaceuticals Limited | D | 47/100 | — | — | — | -0.55% | $3.08B | /tlx-vs-idya → |
| BHC Bausch Health Companies Inc. | C+ | 68/100 | 21.2x | — | 7.6% | -2.19% | $3.07B | /bhc-vs-idya → |
| DYN Dyne Therapeutics Inc. | E | 26/100 | — | — | -35.0% | +3.66% | $3.12B | /dyn-vs-idya → |
| ELVN Enliven Therapeutics Inc. | D- | 39/100 | — | — | -26.2% | +0.86% | $3.24B | /elvn-vs-idya → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), IDEAYA Biosciences Inc. (IDYA) reported GAAP revenue of $218.7M (+3024.4% vs. FY2024 revenue of $7.0M , and +835.3% cumulative change since FY2023) , GAAP net income of -$113.7M, operating cash flow of -$71.1M, and free cash flow of -$73.5M (+70.8% YoY). On the balance sheet, IDYA closed FY2025 with $1.11B in total assets against $0 in total debt (Altman Z-Score: 21.49, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $218.7M | -$113.7M | -$71.1M | -$73.5M | $1.11B | — |
| FY2024 (FY) | 2024-12-31 | $7.0M | -$274.5M | -$247.6M | -$251.4M | $1.12B | — |
| FY2023 (FY) | 2023-12-31 | $23.4M | -$113.0M | -$115.2M | -$115.2M | — | — |
As of 2026-11-03, IDEAYA Biosciences Inc. (NASDAQ: IDYA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $31.64 (-1.00% 1D, market cap $3.08B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IDYA ranks #620 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IDYA carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -13.8%. By comparison, TLX (Telix Pharmaceuticals Limited) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.08B) and BHC (Bausch Health Companies Inc.) posts a C+ grade (68/100 RQD, P/E 21.2x, ROIC 7.6%, cap $3.07B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
Per IDYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001676725), IDEAYA Biosciences Inc. generated $218.7M in revenue (+3024.4% YoY), -$113.7M in net income, and -$73.5M in free cash flow against $1.11B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
IDYA last traded at $31.64 (-1.00% on volume of 789,955 shares), positioning the stock -14.37% below its 50-day simple moving average ($36.95) and -6.89% below its 200-day simple moving average ($33.98). Across its 52-week range of $26.81 to $42.68, IDYA sits at the 30.4% percentile with a 14-day RSI of 36.7 (NEUTRAL RANGE) and an implied next-earnings move of ±8.7% ($28.89 to $34.39).
IDEAYA Biosciences Inc. (IDYA) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $31.64 (-1.00% 1D, market capitalization $3.08B).
IDEAYA Biosciences Inc. (IDYA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The issuer has a market capitalization of $3.2B. — for detailed product or customer descriptions.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), IDEAYA Biosciences Inc. (IDYA) reported $218.7M in annual revenue (up from $7.0M in FY2024, +3024.4% YoY) and -$113.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($23.4M revenue, -$113.0M net income) through FY2025, IDYA scaled operating cash flow to -$71.1M and free cash flow to -$73.5M, backed by $1.11B in total assets against $0 in total debt.
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. Investors should note that the absence of mapped links means no quantified ripple exposure is available here.
Real-time company headlines, analyst actions, and sector developments for IDEAYA Biosciences Inc. (IDYA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
PR Newswire report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering IDEAYA Biosciences Inc. (IDYA) market action, institutional positioning, and fundamental catalysts.
Don't sleep on IDYA's setup in Health Care. Forensic balance sheet scores 14 of 20 with an Altman Z-Score of 21.49 and FY 2025 revenue rising to $218.7M from $7.0M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (34/100) backs up the fundamental quality.
@DeepValue_CFA Agree on the RQD 34/100 quality, though with 1.0 beta I'm scaling in with half-size at $31.96 and keeping dry powder in case we test $29.72.
I respect the product at IDEAYA Biosciences Inc., but the stock at $31.96 is a different story. ROIC of -13.8% and FCF yield of -2.31% leave the cash engine unable to self-fund, with FY 2025 free cash flow at -$73.5M.. FCF yield is -2.31% and RQD sits at 34/100 (E) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: